Investor Relations Overview

Webcast ImageWebcast
AVI BioPharma at Biotechnology Industry Organization (BIO) CEO and Investor Conference (Live)
02/14/12 at 9:30 a.m. ET
AVI BioPharma at Biotechnology Industry Organization (BIO) CEO and Investor Conference
Tuesday, February 14, 2012 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Company Profile

At AVI BioPharma we are focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as select other diseases targets. By leveraging our highly differentiated RNA antisense-based technology platform, we have built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses.

By applying pioneering technologies developed and optimized by AVI, we are able to target a broad range of... 
More >>

Stock Information

AVII (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$1.00
Change (%) Stock is Up 0.06 (6.38%)
Volume1,829,355
Data as of 02/03/12 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent Press Releases

02/02/12AVI BioPharma to Present Company Overview at the 14th Annual BIO CEO & Investor Conference
Webcast Accessible via AVI Website BOTHELL, WA, Feb 02, 2012 (MARKETWIRE via COMTEX) --AVI BioPharma (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that Chris Garabedian, AVI's president and CEO, will present a company overview at 9:30 a.m. EST on Tuesday, Feb. 14, at the 14th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. The presentation will be webcast live under the events section of AVI's website at www.avibio.com and will be ar... 
Printer Friendly Version
01/04/12AVI BioPharma Data Safety Monitoring Board Reports No Safety Concerns Identified in Phase IIb DMD Clinical Trial, Recommends Continuation of Trial
BOTHELL, WA, Jan 04, 2012 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the independent Data Safety Monitoring Board (DSMB) providing oversight for AVI's Phase IIb study of eteplirsen in Duchenne Muscular Dystrophy (DMD) patients has reviewed the 12-week biopsy data from the highest dose cohort (50 mg/kg). Following its assessment of this biopsy data, along with other laboratory results and safety outcomes, the DSMB did ... 
Printer Friendly Version
12/14/11AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
BOTHELL, WA, Dec 14, 2011 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, notifying AVI that for the last 30 consecutive business days the bid price of its common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements set forth in Listing Rule 5450(a)(1). The no... 
Printer Friendly Version
12/09/11AVI BioPharma Names Jayant Aphale, Ph.D., Senior Vice President of Technical Operations
New Hire Is Part of Organizational Restructuring Focused on Improving Operational Efficiencies BOTHELL, WA, Dec 09, 2011 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced the appointment of Jayant Aphale, Ph.D., as Senior Vice President of Technical Operations effective December 12, 2011. Dr. Aphale will have responsibility for all of AVI's internal and outsourced manufacturing activities, with an emphasis on technology transf... 
Printer Friendly Version

More Releases


In the News

New Yorker
October 19, 2011
New Yorker
King5 Healthlink
Chris Garabedian, CEO and Patrick Iversen, PhD,
Senior Vice President of Research and Innovation
September 8, 2011
PharmExec.com
Chris Garabedian, CEO AVI BioPharma
June 10, 2011
New Yorker
The New Yorker
Jan. 31, 2011

Upcoming Events

02/14/12 9:30 a.m. ET
AVI BioPharma at Biotechnology Industry Organization (BIO) CEO and Investor Conference
LocationNew York, NY

More Events


Annual Report

AVI 2010 Annual Report on Form 10-K
AVI 2009 Annual Report on Form 10-K
AVI 2008 Annual Report on Form 10-K
AVI 2007 Annual Report on Form 10-K



This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Learn About Our Corporate PresentationsSign Up For Email Alerts